UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
LVTX holding history
LAVA Therapeutics NV in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LVTX overviewAll 13F holders of LVTXFull Q2 2026 holdings
- Shares (Q4 2025)
- 0
- Sold out in Q4 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | $0 | 0.0% | −15,871−100.0% | Sold out | Holders |
| Q3 2025 | 15,871 | $24.8K | <0.1% | −509−3.1% | Reduced | Holders |
| Q2 2025 | 16,380 | $21.6K | <0.1% | −515−3.0% | Reduced | Holders |
| Q1 2025 | 16,895 | $21.5K | <0.1% | −1,536−8.3% | Reduced | Holders |
| Q4 2024 | 18,431 | $17.5K | <0.1% | +17,359+1,619.3% | Added | Holders |
| Q3 2024 | 1,072 | $1.78K | <0.1% | +1,072 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −8,980−100.0% | Sold out | Holders |
| Q1 2024 | 8,980 | $29.9K | <0.1% | +8,980 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −4,095−100.0% | Sold out | Holders |
| Q1 2023 | 4,095 | $6.80K | <0.1% | +3,094+309.1% | Added | Holders |
| Q4 2022 | 1,001 | $3.50K | <0.1% | +1,001 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −406−100.0% | Sold out | Holders |
| Q2 2022 | 406 | $1.00K | <0.1% | −820−66.9% | Reduced | Holders |
| Q1 2022 | 1,226 | $5.00K | <0.1% | −523−29.9% | Reduced | Holders |
| Q4 2021 | 1,749 | $10.0K | <0.1% | +1,749 | New | Holders |